PATENT CLAIM ANALYSIS

Application Number: 15882724
Application Type: Utility
Filing Date: 2018-01
Publication Date: 2018-06
Patent Classification: ["424", "093210"]

Abstract:
The present disclosure relates to nucleic acid vaccine compositions and methods for preventing or treating pathological conditions, such as cancer or infectious disease. Further, the disclosure provides methods for more efficient production of antigens via mRNA containing one or more non-conventional start codons to promote multiplex initiation of translation in eukaryotic cells.

Claim (Index 13):
The method of  claim 12 , wherein the tumor-associated antigen comprises an antigen associated with breast cancer, triple negative breast cancer, inflammatory breast cancer, ovarian cancer, uterine cancer, colorectal cancer, colon cancer, primary peritoneal cancer, testicular cancer, renal cancer, melanoma, glioblastoma, lung cancer, prostate cancer, or any combination thereof.

Metadata:
- Claim Count in Document: 80.0
- Percentile: 86.0
- Lexical Diversity: 1.21739
- Patent Class: 424.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['15222619', '15180852', '15222627', '14660924', '10343448']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8508742977831029
- 35 USC 102 Novelty (BERT): 0.6717000399071651
- Combined Prediction Score: 0.832956871995509
- Mean Citation Score: 666.5319900000002
- Max Citation Score: 761.4291400000003
- Similarity Product: 640.7433808685638

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test